Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Investing Activities (2018 - 2023)

Marker Therapeutics (MRKR) has disclosed Cash from Investing Activities for 6 consecutive years, with $18.8 million as the latest value for Q2 2023.

  • On a quarterly basis, Cash from Investing Activities rose 928.54% to $18.8 million in Q2 2023 year-over-year; TTM through Dec 2023 was $18.7 million, a 477.42% increase, with the full-year FY2023 number at $18.7 million, up 477.42% from a year prior.
  • Cash from Investing Activities was $18.8 million for Q2 2023 at Marker Therapeutics, up from -$112608.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $18.8 million in Q2 2023 to a low of -$4.1 million in Q4 2020.
  • A 5-year average of $53332.5 and a median of -$286484.5 in 2019 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 31778.1% in 2020, then surged 928.54% in 2023.
  • Marker Therapeutics' Cash from Investing Activities stood at -$12862.0 in 2019, then plummeted by 31778.1% to -$4.1 million in 2020, then soared by 91.47% to -$349843.0 in 2021, then skyrocketed by 63.6% to -$127342.0 in 2022, then skyrocketed by 14845.12% to $18.8 million in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Cash from Investing Activities are $18.8 million (Q2 2023), -$112608.0 (Q1 2023), and -$127342.0 (Q4 2022).